Abstract: The present invention aims at establishing a novel means for purifying norovirus VLPs. There is provided a purification method of norovirus virus-like particles, comprising: contacting solution containing norovirus virus-like particles with support for hydroxyapatite chromatography, binding the virus-like particles to the support, subsequently washing the support with buffer, and then eluting the virus-like particles from the support with buffer containing phosphate, wherein the phosphate concentration of the buffer used for elution is less than 10 mM.

Abstract: The present invention aims at establishing a means for obtaining highly pure virus-like particles by a simple method. There is provided a production method for culture containing virus-like particles, comprising: transforming insect cells with baculovirus vector containing a viral nucleic acid sequence; and cultivating the insect cells, wherein the culture is obtained after continuing cultivating the insect cells until the viability of the insect cells reaches 10% or less.

Abstract: The present invention aims at establishing a novel means for purifying norovirus VLPs. There is provided a purification method of norovirus virus-like particles, comprising: contacting solution containing norovirus virus-like particles with support for hydroxyapatite chromatography, binding the virus-like particles to the support, subsequently washing the support with buffer, and then eluting the virus-like particles from the support with buffer containing phosphate, wherein the phosphate concentration of the buffer used for elution is less than 10 mM.

Abstract: Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity.